|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
63,980,000 |
Market
Cap: |
584.78(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.22 - $11.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 245 |
Guru Rank Value : 4.8 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
Total People Sold |
1 |
2 |
2 |
4 |
Total Sell Transactions |
1 |
3 |
11 |
21 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brady Ann |
President, TBIL |
|
2019-11-20 |
4 |
D |
$17.60 |
$18,885 |
D/D |
(1,073) |
71,111 |
|
- |
|
Worboys Philip D |
SVP, Research & Transl Science |
|
2019-11-20 |
4 |
D |
$17.60 |
$39,987 |
D/D |
(2,272) |
264,855 |
|
- |
|
Sabesan Vijay |
SVP, Technical Operations |
|
2019-11-20 |
4 |
D |
$17.60 |
$25,925 |
D/D |
(1,473) |
146,280 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2019-11-20 |
4 |
D |
$17.60 |
$152,733 |
D/D |
(8,678) |
1,074,455 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2019-11-20 |
4 |
D |
$17.60 |
$47,379 |
D/D |
(2,692) |
231,276 |
|
- |
|
Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
|
2019-11-20 |
4 |
D |
$17.60 |
$39,987 |
D/D |
(2,272) |
259,834 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2019-08-20 |
4 |
D |
$21.51 |
$58,292 |
D/D |
(2,710) |
233,968 |
|
- |
|
Sabesan Vijay |
SVP, Technical Operations |
|
2019-08-20 |
4 |
D |
$21.51 |
$31,663 |
D/D |
(1,472) |
147,753 |
|
- |
|
Pasqualone Frank |
SVP, Chief Comm Ops Officer |
|
2019-08-20 |
4 |
D |
$21.51 |
$50,226 |
D/D |
(2,335) |
320,759 |
|
- |
|
Worboys Philip D |
SVP, Translational Science |
|
2019-08-20 |
4 |
D |
$21.51 |
$48,871 |
D/D |
(2,272) |
267,127 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2019-08-20 |
4 |
D |
$21.51 |
$186,664 |
D/D |
(8,678) |
1,083,133 |
|
- |
|
Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
|
2019-08-20 |
4 |
D |
$21.51 |
$66,337 |
D/D |
(3,084) |
178,901 |
|
- |
|
Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
|
2019-08-20 |
4 |
D |
$21.51 |
$48,871 |
D/D |
(2,272) |
262,106 |
|
- |
|
Hegde Sharathchandra S |
SVP, Research |
|
2019-08-20 |
4 |
D |
$21.51 |
$48,871 |
D/D |
(2,272) |
259,900 |
|
- |
|
Brady Ann |
President, TBIL |
|
2019-08-20 |
4 |
D |
$21.51 |
$23,080 |
D/D |
(1,073) |
72,184 |
|
- |
|
Hindman Andrew A. |
SVP, Chief Financial Officer |
|
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Worboys Philip D |
SVP, Translational Science |
|
2019-05-20 |
4 |
D |
$19.84 |
$45,076 |
D/D |
(2,272) |
269,399 |
|
- |
|
Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
|
2019-05-20 |
4 |
D |
$19.84 |
$49,362 |
D/D |
(2,488) |
181,985 |
|
- |
|
Sabesan Vijay |
SVP, Technical Operations |
|
2019-05-20 |
4 |
D |
$19.84 |
$29,244 |
D/D |
(1,474) |
149,225 |
|
- |
|
Pasqualone Frank |
SVP, Chief Comm Ops Officer |
|
2019-05-20 |
4 |
D |
$19.84 |
$31,823 |
D/D |
(1,604) |
323,094 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2019-05-20 |
4 |
D |
$19.84 |
$172,172 |
D/D |
(8,678) |
1,091,811 |
|
- |
|
Hegde Sharathchandra S |
SVP, Research |
|
2019-05-20 |
4 |
D |
$19.84 |
$45,076 |
D/D |
(2,272) |
262,172 |
|
- |
|
Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
|
2019-05-20 |
4 |
D |
$19.84 |
$45,076 |
D/D |
(2,272) |
264,378 |
|
- |
|
Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
|
2019-05-20 |
4 |
D |
$19.84 |
$53,667 |
D/D |
(2,705) |
236,678 |
|
- |
|
Brady Ann |
President, TBIL |
|
2019-05-20 |
4 |
D |
$19.84 |
$21,288 |
D/D |
(1,073) |
73,257 |
|
- |
|
529 Records found
|
|
Page 10 of 22 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|